Emerging Treatment Options for the Treatment of Metastatic Urothelial Cancer: Therapeutic Potential of Enfortumab Vedotin
Rohit K Jain, William Paul Skelton IV, Jingsong Zhang Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USACorrespondence: Jingsong ZhangDepartment of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, 12902 USF Magnolia D...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2020-09-01
|
| Series: | Cancer Management and Research |
| Subjects: | |
| Online Access: | https://www.dovepress.com/emerging-treatment-options-for-the-treatment-of-metastatic-urothelial--peer-reviewed-article-CMAR |
| _version_ | 1818039828205273088 |
|---|---|
| author | Jain RK Skelton WP IV Zhang J |
| author_facet | Jain RK Skelton WP IV Zhang J |
| author_sort | Jain RK |
| collection | DOAJ |
| description | Rohit K Jain, William Paul Skelton IV, Jingsong Zhang Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USACorrespondence: Jingsong ZhangDepartment of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, 12902 USF Magnolia Drive, Tampa, FL 33612, USAEmail Jingsong.zhang@moffitt.orgAbstract: Enfortumab vedotin (EV) is an antibody–drug conjugate with humanized anti-Nectin-4 antibody linked with a microtubule-disrupting agent called monomethyl auristatin E. Nectin-4 is a cellular adhesion protein that is overexpressed in urothelial cancer. EV was approved in December 2019 for patients with locally advanced or metastatic urothelial cancer who previously received platinum-based chemotherapy and immune checkpoint inhibitors. Here, we reviewed the clinical efficacy and safety data that led to the accelerated approval of EV for treating patients with metastatic urothelial cancer. Emerging clinical data on EV-based combinational therapeutic trials for metastatic urothelial cancer were also reviewed.Keywords: enfortumab vedotin, urothelial cancer, antibody-drug conjugate |
| first_indexed | 2024-12-10T08:04:50Z |
| format | Article |
| id | doaj.art-debbe2030404424dabf719e87431a0e2 |
| institution | Directory Open Access Journal |
| issn | 1179-1322 |
| language | English |
| last_indexed | 2024-12-10T08:04:50Z |
| publishDate | 2020-09-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Cancer Management and Research |
| spelling | doaj.art-debbe2030404424dabf719e87431a0e22022-12-22T01:56:42ZengDove Medical PressCancer Management and Research1179-13222020-09-01Volume 128379838656963Emerging Treatment Options for the Treatment of Metastatic Urothelial Cancer: Therapeutic Potential of Enfortumab VedotinJain RKSkelton WP IVZhang JRohit K Jain, William Paul Skelton IV, Jingsong Zhang Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USACorrespondence: Jingsong ZhangDepartment of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, 12902 USF Magnolia Drive, Tampa, FL 33612, USAEmail Jingsong.zhang@moffitt.orgAbstract: Enfortumab vedotin (EV) is an antibody–drug conjugate with humanized anti-Nectin-4 antibody linked with a microtubule-disrupting agent called monomethyl auristatin E. Nectin-4 is a cellular adhesion protein that is overexpressed in urothelial cancer. EV was approved in December 2019 for patients with locally advanced or metastatic urothelial cancer who previously received platinum-based chemotherapy and immune checkpoint inhibitors. Here, we reviewed the clinical efficacy and safety data that led to the accelerated approval of EV for treating patients with metastatic urothelial cancer. Emerging clinical data on EV-based combinational therapeutic trials for metastatic urothelial cancer were also reviewed.Keywords: enfortumab vedotin, urothelial cancer, antibody-drug conjugatehttps://www.dovepress.com/emerging-treatment-options-for-the-treatment-of-metastatic-urothelial--peer-reviewed-article-CMARenfortumab vedotinurothelial cancerantibody-drug conjugate |
| spellingShingle | Jain RK Skelton WP IV Zhang J Emerging Treatment Options for the Treatment of Metastatic Urothelial Cancer: Therapeutic Potential of Enfortumab Vedotin Cancer Management and Research enfortumab vedotin urothelial cancer antibody-drug conjugate |
| title | Emerging Treatment Options for the Treatment of Metastatic Urothelial Cancer: Therapeutic Potential of Enfortumab Vedotin |
| title_full | Emerging Treatment Options for the Treatment of Metastatic Urothelial Cancer: Therapeutic Potential of Enfortumab Vedotin |
| title_fullStr | Emerging Treatment Options for the Treatment of Metastatic Urothelial Cancer: Therapeutic Potential of Enfortumab Vedotin |
| title_full_unstemmed | Emerging Treatment Options for the Treatment of Metastatic Urothelial Cancer: Therapeutic Potential of Enfortumab Vedotin |
| title_short | Emerging Treatment Options for the Treatment of Metastatic Urothelial Cancer: Therapeutic Potential of Enfortumab Vedotin |
| title_sort | emerging treatment options for the treatment of metastatic urothelial cancer therapeutic potential of enfortumab vedotin |
| topic | enfortumab vedotin urothelial cancer antibody-drug conjugate |
| url | https://www.dovepress.com/emerging-treatment-options-for-the-treatment-of-metastatic-urothelial--peer-reviewed-article-CMAR |
| work_keys_str_mv | AT jainrk emergingtreatmentoptionsforthetreatmentofmetastaticurothelialcancertherapeuticpotentialofenfortumabvedotin AT skeltonwpiv emergingtreatmentoptionsforthetreatmentofmetastaticurothelialcancertherapeuticpotentialofenfortumabvedotin AT zhangj emergingtreatmentoptionsforthetreatmentofmetastaticurothelialcancertherapeuticpotentialofenfortumabvedotin |